Discover Upperton's Oral Dosage Form Capabilities
Oral administration remains the most widely used route for the successful delivery of active pharmaceuticals to patients. Discover how a CDMO partnership can streamline your drug development journey.
Oral Solid Dosage Forms: Choices for FIH Studies
Nose to Brain Drug Delivery
Discover Upperton's Nasal Dosage Form Capabilities
The ability to self-administer small molecules, biologics and vaccines is highly attractive. Discover Upperton's knowledge and expertise in rapidly developing products for this alternative delivery route.
Let's work together
How can we help you?
Discover Upperton's Clinical Manufacturing Capabilities
We provide a flexible and dynamic approach to GMP manufacturing. From first in human (FIH) through to phase III clinical supplies manufacturing at our MHRA Approved and Home Office Approved (I-IV) GMP facility, Trent Gateway.
Essential Guide to Clinical Trial Manufacturing
Discover Upperton's Clinical Manufacturing Capabilities
The Importance of a CDMO
Formulation
Development
Our team has extensive experience in selecting the correct oral, nasal and pulmonary dosage forms to ensure success in getting to the clinic.
- Formulation and analytical development
- Toxicology supplies
- ASAP stability to support clinical prototype selection
Phase 1 - Phase 2 Clinical Supply
We can help you accelerate to Phase 1 clinical trials through formulation optimisation and identify the next steps to transition into Phase 2 clinical trials following Phase 1 data.
- Clinical manufacturing and QC testing
- Qualified Person Release
- Clinical stability
Process Scale-Up for Phase 3
We understand the complexities of scale up and technical transfer. Covering all aspects from equipment consideration through to manufacturing handover and QC.
- Process optimisation robustness (Qbd, DoE)
- Method validation
- Cleaning validation
Discover Upperton's Capabilities
Additional Resources
Choosing the right CDMO partner is a critical decision in drug development. The collaboration between pharmaceutical companies and contract development and manufacturing organisations (CDMOs) provides access to specialised expertise and manufacturing services.
Learn more about how pharmaceutical companies should select the right CDMO for their needs.
Outsourcing to Contract Development and Manufacturing Organisations (CDMOs) has become a strategic approach to enhance efficiency and reduce costs. By partnering with a CDMO, you can leverage specialised expertise and resources, allowing your company to focus on core competencies such as research and development.
Learn more about CDMO Outsourcing.
A Contract Development and Manufacturing Organisation (CDMO) contract is a formal agreement between a pharmaceutical company and a CDMO. This contract outlines the terms under which the CDMO will provide services such as drug development, manufacturing, and related support. Establishing a clear and comprehensive CDMO contract is essential for both parties to ensure mutual understanding and successful collaboration.
Learn more about CDMO Contracts.
